Saturday, October 20, 2018
Home Conference Coverage

Conference Coverage

With nearly 16 million long-term cancer survivors, the treatment and care of patients with cancer has changed. But long-term cancer survivors may be plagued by chronic pain sequelae. To help these patients, researchers have identified the potential of strong...
People living with cancer face major financial difficulties. This is a conclusion based on a number of studies to be presented during the upcoming American Society of Clinical Oncology’s (ASCO) Quality Care Symposium, taking place September 28 and 29, 2018...
According to new research from the University of Rochester, 18% of older patients with advanced cancer are experiencing financial difficulties due to the cost of their treatment that are negatively affecting their care, quality of life, and mental health. The...
Results of a new study reveal that many women with breast cancer experience significant financial burden. Most of these women, 8 out of 10, prefer to discuss the cost of their cancer care at the time of their diagnosis...
A recent review of patient-caregiver communities focused on non-small cell lung cancer (NSCLC) with genomic alterations show that these groups are improving outcomes by supporting patients and caregivers, increasing awareness and education and accelerating research. These findings were presented during...
The multidisciplinary 20th World Congress on Gastrointestinal Cancer, held June 20 - 23, 2018 in The International Convention Center of Barcelona in Barcelona, Spain, brought together nearly 3,500 participants from 90 countries to discuss strategies to improve the outcomes...
The 53rd annual meeting of the American Society of Clinical Oncology (ASCO), starts today. Being held from June 2 to June 6, 2017 at the McCormick Place in Chicago, Ill., this annual event fosters communication among oncology-related sub-specialties, as...
In a phase II study, IMvigor 210, atezolizumab (Tecentriq™; Genentech, a member of the Roche Group) shrank tumors (objective response rate, ORR) in 24% (n=28) of people with locally advanced or metastatic urothelial carcinoma (mUC) who have not received...
Adding the chemotherapy drug carboplatin (Paraplatin®; Bristol-Myers Squibb)and/or the antibody therapy bevacizumab (Avastin®; Genentech/Roche) to standardpre-surgery anthracycline- and taxane-based neoadjuvant chemotherapy (NAC) increased the number of women with triple-negative breast cancer (TNBC) without residual cancer detected at surgery. This...
Breast cancer patients with residual disease after neo-adjuvant chemotherapy (NACT) are considered to have chemo-resistant cancer and adjuvant treatment with bisphosphonates, such as zoledronic acid or zoledronate(Zometa®; Novartis) is considered to reduce the relapse risk predominantly in estrogen-deprivated patients....

Related articles